Advertisement

Topics

Moderate Psoriasis - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Moderate Psoriasis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 137-page report is available in PDF from $2000.

Moderate Psoriasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Moderate Psoriasis - Pipeline Review, H1 2015’, provides an overview of the Moderate Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Moderate Psoriasis Overview 9
Therapeutics Development 10
Pipeline Products for Moderate Psoriasis - Overview 10
Pipeline Products for Moderate Psoriasis - Comparative Analysis 11
Moderate Psoriasis - Therapeutics under Development by Companies 12
Moderate Psoriasis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Moderate Psoriasis - Products under Development by Companies 17
Moderate Psoriasis - Companies Involved in Therapeutics Development 20
AbGenomics International, Inc. 20
Almirall, S.A. 21
Amgen Inc. 22
ApoPharma Inc. 23
Avexxin AS 24
Boehringer Ingelheim GmbH 25
Convoy Therapeutics, Inc. 26
Covagen AG 27
Delenex Therapeutics AG 28
Eli Lilly and Company 29
GlycoMar Limited 30
Idera Pharmaceuticals, Inc. 31
Johnson & Johnson 32
Merck KGaA 33
OPKO Health, Inc. 34
Pfizer Inc. 35
Sandoz International GmbH 36
Soligenix, Inc. 37
Sun Pharmaceutical Industries Inc. 38
Syntrix Biosystems, Inc. 39
UCB S.A. 40
Valeant Pharmaceuticals International, Inc. 41
XenoPort, Inc. 42
Moderate Psoriasis - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
AbGn-168H - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
adalimumab biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
adalimumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AKP-11 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
aminopterin sodium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AVX-001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
baricitinib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BI-655066 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
brodalumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
certolizumab pegol - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
COVA-322 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
cyclosporine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
dimethyl fumarate - Drug Profile 74
Product Description…

For more information open Moderate Psoriasis - Pipeline Review, H1 2015.

SKU: GMDHC6598IDB

Original Article: Moderate Psoriasis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Moderate Psoriasis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...